Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers

Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults

ClinicalTrials.gov ID: NCT04657172

Public ClinicalTrials.gov record NCT04657172. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 1:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Study of the Safety and Efficacy of 1% and 2% Pilocarpine Ophthalmic Solutions Administered With the Optejet® Microdose Dispenser for Temporary Improvement of Near Vision in Adults With Presbyopia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Volunteer participants are evaluated for eligibility during a Screening Visit; those meeting study inclusion/exclusion criteria are scheduled for 3 treatment visits. At each treatment visit, 1 of the 3 study solutions is self-administered to both eyes. Afterwards, efficacy and safety assessments are performed over a 3-hour period.

Study identification

NCT ID
NCT04657172
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Eyenovia Inc.
Industry
Enrollment
84 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
40 Years to 60 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 14, 2020
Primary completion
Mar 25, 2021
Completion
Mar 25, 2021
Last update posted
Aug 8, 2021

2020 – 2021

United States locations

U.S. sites
9
U.S. states
7
U.S. cities
9
Facility City State ZIP Site status
VISION-1 Study Site #21 Azusa California 91702
VISION-1 Study Site #52 Newport Beach California 92663
VISION-1 Study Site #54 Fort Collins Colorado 80528
VISION-1 Study Site #53 Orlando Florida 32803
VISION-1 Study Site #50 New York New York 10036
VISION-1 Study Site #17 High Point North Carolina 27262
VISION-1 Study Site #22 Raleigh North Carolina 27603
VISION-1 Study Site #51 Cranberry Township Pennsylvania 16066
VISION-1 Study Site #03 San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04657172, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 8, 2021 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04657172 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →